On December 8, New Health Cheng (831193) recently announced that in order to improve the efficiency of the use of the company's idle own funds, the company held the eighth meeting of the fourth board of directors on December 8, 2023, and deliberated and passed the "Proposal on the Use of Idle Own Funds for Cash Management", and agreed that under the premise of ensuring the safety of funds, not affecting the normal capital turnover operation, and effectively controlling risks, the amount of cash management using idle own funds shall not exceed 150. 000,000 yuan, the term of the investment product is 12 months, and the funds can be used on a rolling basis within the above limit. The proceeds from cash management can be reinvested in principal-protected investment products, but the reinvested amount is not included in the above amount.
The specifics of financial assets:
Investment product variety: principal-guaranteed wealth management products with high security and strong liquidity.
Investment quota: The amount of cash management that the company intends to use idle own funds for cash management shall not exceed RMB150,000,000, that is, the total amount of unexpired investment products held at any point in the investment period shall not exceed RMB150,000,000 (including RMB150,000,000), and the funds within the above quota can be used on a rolling basis.
Investment period: Without affecting the normal use of the company's funds, the investment period of cash management shall not exceed 12 months (including 12 months), which shall be valid for one year from the date when this proposal is deliberated and approved by the company's sixth extraordinary general meeting of shareholders in 2023.
Implementation method: Within the scope of the above quota, the general manager is authorized to exercise the decision-making power of cash management investment, and the specific cash management activities are organized and implemented by the company's finance department.
Income distribution method of cash management: subject to the agreement actually signed between the company and the bank or financial institution.
The company adheres to the principle of standardized operation, value preservation and appreciation, and risk prevention for cash management of idle own funds, which will not affect the company's daily production and operation of funds, and through moderate cash management, it can improve the efficiency of capital use, obtain certain investment benefits, improve the overall performance level of the company, and seek more investment returns for the company's shareholders.
According to the data of digbei.com, New Health Cheng focuses on the in vitro diagnostic industry and is a high-tech enterprise specializing in the research and development, production, sales and service of in vitro diagnostic reagents and supporting instruments, calibrators and quality controls.